Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Apalutamide Sensitizes Prostate Cancer to Ionizing Radiation via Inhibition of Non-Homologous End-Joining DNA Repair.

Zhang W, Liao CY, Chtatou H, Incrocci L, van Gent DC, van Weerden WM, Nonnekens J.

Cancers (Basel). 2019 Oct 18;11(10). pii: E1593. doi: 10.3390/cancers11101593.

2.

Hybrid Tracers Based on Cyanine Backbones Targeting Prostate-Specific Membrane Antigen - Tuning Pharmacokinetic Properties and Exploring Dye-Protein Interaction.

Hensbergen AW, Buckle T, van Willigen DM, Schottelius M, Welling MM, van der Wijk FA, Maurer T, van der Poel HG, van der Pluijm G, van Weerden WM, Wester HJ, van Leeuwen FWB.

J Nucl Med. 2019 Sep 3. pii: jnumed.119.233064. doi: 10.2967/jnumed.119.233064. [Epub ahead of print]

PMID:
31481575
3.

Correction to: Role of the DNA damage response in prostate cancer formation, progression and treatment.

Zhang W, van Gent DC, Incrocci L, van Weerden WM, Nonnekens J.

Prostate Cancer Prostatic Dis. 2019 Jul 17. doi: 10.1038/s41391-019-0162-1. [Epub ahead of print]

PMID:
31316184
4.

Role of the DNA damage response in prostate cancer formation, progression and treatment.

Zhang W, van Gent DC, Incrocci L, van Weerden WM, Nonnekens J.

Prostate Cancer Prostatic Dis. 2019 Jun 13. doi: 10.1038/s41391-019-0153-2. [Epub ahead of print] Erratum in: Prostate Cancer Prostatic Dis. 2019 Jul 17;:.

PMID:
31197228
5.

AR splice variants in circulating tumor cells of patients with castration-resistant prostate cancer: relation with outcome to cabazitaxel.

Sieuwerts AM, Onstenk W, Kraan J, Beaufort CM, Van M, De Laere B, Dirix LY, Hamberg P, Beeker A, Meulenbeld HJ, Creemers GJ, van Weerden WM, Jenster GW, Nieuweboer AJM, Mathijssen RHJ, de Wit R, Martens JWM, Sleijfer S.

Mol Oncol. 2019 Aug;13(8):1795-1807. doi: 10.1002/1878-0261.12529. Epub 2019 Jun 28.

6.

A bypass mechanism of abiraterone-resistant prostate cancer: Accumulating CYP17A1 substrates activate androgen receptor signaling.

Moll JM, Kumagai J, van Royen ME, Teubel WJ, van Soest RJ, French PJ, Homma Y, Jenster G, de Wit R, van Weerden WM.

Prostate. 2019 Jun;79(9):937-948. doi: 10.1002/pros.23799. Epub 2019 Apr 24.

7.

Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.

Hassani M, Hajari Taheri F, Sharifzadeh Z, Arashkia A, Hadjati J, van Weerden WM, Modarressi MH, Abolhassani M.

J Cell Biochem. 2019 Jun;120(6):10787-10795. doi: 10.1002/jcb.28370. Epub 2019 Jan 22.

PMID:
30672018
8.

Ex vivo treatment of prostate tumor tissue recapitulates in vivo therapy response.

Zhang W, van Weerden WM, de Ridder CMA, Erkens-Schulze S, Schönfeld E, Meijer TG, Kanaar R, van Gent DC, Nonnekens J.

Prostate. 2019 Mar;79(4):390-402. doi: 10.1002/pros.23745. Epub 2018 Dec 5.

9.

The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models.

Handle F, Puhr M, Schaefer G, Lorito N, Hoefer J, Gruber M, Guggenberger F, Santer FR, Marques RB, van Weerden WM, Claessens F, Erb HHH, Culig Z.

Mol Cancer Ther. 2018 Dec;17(12):2722-2731. doi: 10.1158/1535-7163.MCT-18-0508. Epub 2018 Sep 25.

PMID:
30254184
10.

Tumor heterogeneity, aggressiveness, and immune cell composition in a novel syngeneic PSA-targeted Pten knockout mouse prostate cancer (MuCaP) model.

van Duijn PW, Marques RB, Ziel-van der Made ACJ, van Zoggel HJAA, Aghai A, Berrevoets C, Debets R, Jenster G, Trapman J, van Weerden WM.

Prostate. 2018 Sep;78(13):1013-1023. doi: 10.1002/pros.23659. Epub 2018 May 29.

PMID:
30133757
11.

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E.

Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2.

PMID:
30073676
12.

Protocols and characterization data for 2D, 3D, and slice-based tumor models from the PREDECT project.

de Hoogt R, Estrada MF, Vidic S, Davies EJ, Osswald A, Barbier M, Santo VE, Gjerde K, van Zoggel HJAA, Blom S, Dong M, Närhi K, Boghaert E, Brito C, Chong Y, Sommergruber W, van der Kuip H, van Weerden WM, Verschuren EW, Hickman J, Graeser R.

Sci Data. 2017 Nov 21;4:170170. doi: 10.1038/sdata.2017.170.

13.

Endogenous androgen receptor proteomic profiling reveals genomic subcomplex involved in prostate tumorigenesis.

Stelloo S, Nevedomskaya E, Kim Y, Hoekman L, Bleijerveld OB, Mirza T, Wessels LFA, van Weerden WM, Altelaar AFM, Bergman AM, Zwart W.

Oncogene. 2018 Jan 18;37(3):313-322. doi: 10.1038/onc.2017.330. Epub 2017 Sep 18.

PMID:
28925401
14.

213Bi-Labeled Prostate-Specific Membrane Antigen-Targeting Agents Induce DNA Double-Strand Breaks in Prostate Cancer Xenografts.

Nonnekens J, Chatalic KL, Molkenboer-Kuenen JD, Beerens CE, Bruchertseifer F, Morgenstern A, Veldhoven-Zweistra J, Schottelius M, Wester HJ, van Gent DC, van Weerden WM, Boerman OC, de Jong M, Heskamp S.

Cancer Biother Radiopharm. 2017 Mar;32(2):67-73. doi: 10.1089/cbr.2016.2155.

PMID:
28301262
15.

Loss of SLCO1B3 drives taxane resistance in prostate cancer.

de Morrée ES, Böttcher R, van Soest RJ, Aghai A, de Ridder CM, Gibson AA, Mathijssen RH, Burger H, Wiemer EA, Sparreboom A, de Wit R, van Weerden WM.

Br J Cancer. 2016 Sep 6;115(6):674-81. doi: 10.1038/bjc.2016.251. Epub 2016 Aug 18.

16.

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent.

Chatalic KL, Heskamp S, Konijnenberg M, Molkenboer-Kuenen JD, Franssen GM, Clahsen-van Groningen MC, Schottelius M, Wester HJ, van Weerden WM, Boerman OC, de Jong M.

Theranostics. 2016 Apr 12;6(6):849-61. doi: 10.7150/thno.14744. eCollection 2016.

17.

Characterization of Heterogeneous Prostate Tumors in Targeted Pten Knockout Mice.

Korsten H, Ziel-van der Made AC, van Weerden WM, van der Kwast T, Trapman J, Van Duijn PW.

PLoS One. 2016 Jan 25;11(1):e0147500. doi: 10.1371/journal.pone.0147500. eCollection 2016.

18.

Imaging heterogeneity of peptide delivery and binding in solid tumors using SPECT imaging and MRI.

Haeck JC, Bol K, de Ridder CM, Brunel L, Fehrentz JA, Martinez J, van Weerden WM, Bernsen MR, de Jong M, Veenland JF.

EJNMMI Res. 2016 Dec;6(1):3. doi: 10.1186/s13550-016-0160-4. Epub 2016 Jan 14.

19.

In Vivo Stabilization of a Gastrin-Releasing Peptide Receptor Antagonist Enhances PET Imaging and Radionuclide Therapy of Prostate Cancer in Preclinical Studies.

Chatalic KL, Konijnenberg M, Nonnekens J, de Blois E, Hoeben S, de Ridder C, Brunel L, Fehrentz JA, Martinez J, van Gent DC, Nock BA, Maina T, van Weerden WM, de Jong M.

Theranostics. 2016 Jan 1;6(1):104-17. doi: 10.7150/thno.13580. eCollection 2016.

20.

Capturing complex tumour biology in vitro: histological and molecular characterisation of precision cut slices.

Davies EJ, Dong M, Gutekunst M, Närhi K, van Zoggel HJ, Blom S, Nagaraj A, Metsalu T, Oswald E, Erkens-Schulze S, Delgado San Martin JA, Turkki R, Wedge SR, af Hällström TM, Schueler J, van Weerden WM, Verschuren EW, Barry ST, van der Kuip H, Hickman JA.

Sci Rep. 2015 Dec 9;5:17187. doi: 10.1038/srep17187.

21.
22.

Efficacy of Cabazitaxel in Castration-resistant Prostate Cancer Is Independent of the Presence of AR-V7 in Circulating Tumor Cells.

Onstenk W, Sieuwerts AM, Kraan J, Van M, Nieuweboer AJ, Mathijssen RH, Hamberg P, Meulenbeld HJ, De Laere B, Dirix LY, van Soest RJ, Lolkema MP, Martens JW, van Weerden WM, Jenster GW, Foekens JA, de Wit R, Sleijfer S.

Eur Urol. 2015 Dec;68(6):939-45. doi: 10.1016/j.eururo.2015.07.007. Epub 2015 Jul 15.

PMID:
26188394
23.

A Novel ¹¹¹In-Labeled Anti-Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer.

Chatalic KL, Veldhoven-Zweistra J, Bolkestein M, Hoeben S, Koning GA, Boerman OC, de Jong M, van Weerden WM.

J Nucl Med. 2015 Jul;56(7):1094-9. doi: 10.2967/jnumed.115.156729. Epub 2015 May 14.

24.

Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.

van Soest RJ, de Morrée ES, Kweldam CF, de Ridder CMA, Wiemer EAC, Mathijssen RHJ, de Wit R, van Weerden WM.

Eur Urol. 2015 Jun;67(6):981-985. doi: 10.1016/j.eururo.2014.11.033. Epub 2014 Dec 4.

PMID:
25484141
25.

Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancer.

Chatalic KL, Franssen GM, van Weerden WM, McBride WJ, Laverman P, de Blois E, Hajjaj B, Brunel L, Goldenberg DM, Fehrentz JA, Martinez J, Boerman OC, de Jong M.

J Nucl Med. 2014 Dec;55(12):2050-6. doi: 10.2967/jnumed.114.141143. Epub 2014 Nov 20.

26.

Nuclear Eg5 (kinesin spindle protein) expression predicts docetaxel response and prostate cancer aggressiveness.

Wissing MD, De Morrée ES, Dezentjé VO, Buijs JT, De Krijger RR, Smit VT, Van Weerden WM, Gelderblom H, van der Pluijm G.

Oncotarget. 2014 Sep 15;5(17):7357-67.

27.

High Efficacy of Combination Therapy Using PI3K/AKT Inhibitors with Androgen Deprivation in Prostate Cancer Preclinical Models.

Marques RB, Aghai A, de Ridder CMA, Stuurman D, Hoeben S, Boer A, Ellston RP, Barry ST, Davies BR, Trapman J, van Weerden WM.

Eur Urol. 2015 Jun;67(6):1177-1185. doi: 10.1016/j.eururo.2014.08.053. Epub 2014 Sep 12.

PMID:
25220373
29.

Imaging preclinical tumour models: improving translational power.

de Jong M, Essers J, van Weerden WM.

Nat Rev Cancer. 2014 Jul;14(7):481-93. doi: 10.1038/nrc3751. Epub 2014 Jun 19. Review.

PMID:
24943811
30.

Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer.

van Soest RJ, van Royen ME, de Morrée ES, Moll JM, Teubel W, Wiemer EA, Mathijssen RH, de Wit R, van Weerden WM.

Eur J Cancer. 2013 Dec;49(18):3821-30. doi: 10.1016/j.ejca.2013.09.026. Epub 2013 Oct 24.

PMID:
24200698
31.

Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.

Kumagai J, Hofland J, Erkens-Schulze S, Dits NF, Steenbergen J, Jenster G, Homma Y, de Jong FH, van Weerden WM.

Prostate. 2013 Nov;73(15):1636-50. doi: 10.1002/pros.22655. Epub 2013 Sep 2.

PMID:
23996639
32.

Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-mediated imaging of prostate cancer.

De Blois E, Schroeder RP J, De Ridder CM A, Van Weerden WM, Breeman WA P, De Jong M.

Q J Nucl Med Mol Imaging. 2013 Jun 19. [Epub ahead of print]

PMID:
23778459
33.

Improving radiopeptide pharmacokinetics by adjusting experimental conditions for bombesin receptor-targeted imaging of prostate cancer.

Schroeder RP, De Blois E, De Ridder CM, Van Weerden WM, Breeman WA, de Jong M.

Q J Nucl Med Mol Imaging. 2012 Oct;56(5):468-75.

PMID:
23069925
34.

Activin A stimulates AKR1C3 expression and growth in human prostate cancer.

Hofland J, van Weerden WM, Steenbergen J, Dits NF, Jenster G, de Jong FH.

Endocrinology. 2012 Dec;153(12):5726-34. doi: 10.1210/en.2011-2065. Epub 2012 Sep 28.

PMID:
23024260
35.

Profiling of antibody production against xenograft-released proteins by protein microarrays discovers prostate cancer markers.

Jansen FH, van Rijswijk A, Teubel W, van Weerden WM, Reneman S, van den Bemd GJ, Roobol MJ, Bangma CH, Staal FJ, Jenster G.

J Proteome Res. 2012 Feb 3;11(2):728-35. doi: 10.1021/pr2006473. Epub 2011 Dec 22.

PMID:
22136385
36.

ERG immunohistochemistry is not predictive for PSA recurrence, local recurrence or overall survival after radical prostatectomy for prostate cancer.

Hoogland AM, Jenster G, van Weerden WM, Trapman J, van der Kwast T, Roobol MJ, Schröder FH, Wildhagen MF, van Leenders GJ.

Mod Pathol. 2012 Mar;25(3):471-9. doi: 10.1038/modpathol.2011.176. Epub 2011 Nov 11.

37.

A transductionally retargeted adenoviral vector for virotherapy of Her2/neu-expressing prostate cancer.

Magnusson MK, Kraaij R, Leadley RM, De Ridder CM, van Weerden WM, Van Schie KA, Van der Kroeg M, Hoeben RC, Maitland NJ, Lindholm L.

Hum Gene Ther. 2012 Jan;23(1):70-82. doi: 10.1089/hum.2011.016. Epub 2011 Oct 12.

38.

Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody.

van Rij CM, Sharkey RM, Goldenberg DM, Frielink C, Molkenboer JD, Franssen GM, van Weerden WM, Oyen WJ, Boerman OC.

J Nucl Med. 2011 Oct;52(10):1601-7. doi: 10.2967/jnumed.110.086520. Epub 2011 Aug 24.

39.

Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines.

Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM, Jenster G.

PLoS One. 2011;6(8):e23144. doi: 10.1371/journal.pone.0023144. Epub 2011 Aug 4.

40.

Do androgens control the uptake of 18F-FDG, 11C-choline and 11C-acetate in human prostate cancer cell lines?

Emonds KM, Swinnen JV, van Weerden WM, Vanderhoydonc F, Nuyts J, Mortelmans L, Mottaghy FM.

Eur J Nucl Med Mol Imaging. 2011 Oct;38(10):1842-53. doi: 10.1007/s00259-011-1861-6. Epub 2011 Jul 6.

PMID:
21732108
41.

Disconnecting the yin and yang relation of epidermal growth factor receptor (EGFR)-mediated delivery: a fully synthetic, EGFR-targeted gene transfer system avoiding receptor activation.

Schäfer A, Pahnke A, Schaffert D, van Weerden WM, de Ridder CM, Rödl W, Vetter A, Spitzweg C, Kraaij R, Wagner E, Ogris M.

Hum Gene Ther. 2011 Dec;22(12):1463-73. doi: 10.1089/hum.2010.231. Epub 2011 Aug 10.

42.

The miR-15a-miR-16-1 locus is homozygously deleted in a subset of prostate cancers.

Porkka KP, Ogg EL, Saramäki OR, Vessella RL, Pukkila H, Lähdesmäki H, van Weerden WM, Wolf M, Kallioniemi OP, Jenster G, Visakorpi T.

Genes Chromosomes Cancer. 2011 Jul;50(7):499-509. doi: 10.1002/gcc.20873. Epub 2011 Mar 31.

PMID:
21472816
43.

Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts.

Schroeder RP, van Weerden WM, Krenning EP, Bangma CH, Berndsen S, Grievink-de Ligt CH, Groen HC, Reneman S, de Blois E, Breeman WA, de Jong M.

Eur J Nucl Med Mol Imaging. 2011 Jul;38(7):1257-66. doi: 10.1007/s00259-011-1775-3. Epub 2011 Mar 23.

44.

Overexpression of full-length ETV1 transcripts in clinical prostate cancer due to gene translocation.

Gasi D, van der Korput HA, Douben HC, de Klein A, de Ridder CM, van Weerden WM, Trapman J.

PLoS One. 2011 Jan 26;6(1):e16332. doi: 10.1371/journal.pone.0016332.

45.

Bypass mechanisms of the androgen receptor pathway in therapy-resistant prostate cancer cell models.

Marques RB, Dits NF, Erkens-Schulze S, van Weerden WM, Jenster G.

PLoS One. 2010 Oct 19;5(10):e13500. doi: 10.1371/journal.pone.0013500.

46.

A standardised study to compare prostate cancer targeting efficacy of five radiolabelled bombesin analogues.

Schroeder RP, Müller C, Reneman S, Melis ML, Breeman WA, de Blois E, Bangma CH, Krenning EP, van Weerden WM, de Jong M.

Eur J Nucl Med Mol Imaging. 2010 Jul;37(7):1386-96. doi: 10.1007/s00259-010-1388-2. Epub 2010 Feb 25.

47.

Genetic alterations and changes in expression of histone demethylases in prostate cancer.

Suikki HE, Kujala PM, Tammela TL, van Weerden WM, Vessella RL, Visakorpi T.

Prostate. 2010 Jun 1;70(8):889-98. doi: 10.1002/pros.21123.

PMID:
20127736
48.

Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.

Hofland J, van Weerden WM, Dits NF, Steenbergen J, van Leenders GJ, Jenster G, Schröder FH, de Jong FH.

Cancer Res. 2010 Feb 1;70(3):1256-64. doi: 10.1158/0008-5472.CAN-09-2092. Epub 2010 Jan 19.

49.

Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.

Schroeder RP, de Visser M, van Weerden WM, de Ridder CM, Reneman S, Melis M, Breeman WA, Krenning EP, de Jong M.

Int J Cancer. 2010 Jun 15;126(12):2826-34. doi: 10.1002/ijc.25000.

50.

Prostate cancer--chemoprevention.

Schröder FH, van Weerden WM.

Eur J Cancer. 2009 Sep;45 Suppl 1:355-9. doi: 10.1016/S0959-8049(09)70050-4. Review. No abstract available.

PMID:
19775632

Supplemental Content

Loading ...
Support Center